Background: Extended thromboprophylaxis has not been widely implemented in acutely ill medical patients because of bleeding concerns. The MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin) and MARINER (Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk) trials evaluated whether rivaroxaban compared with enoxaparin or placebo could prevent venous thromboembolism without increased bleeding. We hypothesized that patients with major bleeding but not those with nonmajor clinically relevant bleeding would be at an increased risk of all-cause mortality (ACM).
Methods: We evaluated all bleeding events in patients taking at least 1 dose of study drug and their association with ACM in 4 mutually exclusive groups: (1) no bleeding, or first event was (2) nonmajor clinically relevant bleeding, (3) major bleeding, or (4) trivial bleeding. Using a Cox proportional hazards model adjusted for differences in baseline characteristics associated with ACM, we assessed the risk of ACM after such events.
Results: Compared with patients with no bleeding, the risk of ACM for patients with nonmajor clinically relevant bleeding was not increased in MARINER (hazard ratio, 0.43; =0.235) but was increased in MAGELLAN (hazard ratio, 1.74; =0.021). Major bleeding was associated with a higher incidence of ACM in both studies, whereas trivial bleeding was not associated with ACM in either study.
Conclusions: Patients with major bleeding had an increased risk of ACM, whereas nonmajor clinically relevant bleeding was not consistently associated with an increased risk of death. These results inform the risk-benefit calculus of extended thromboprophylaxis in medically ill patients.
Registration: URL: https://www.
Clinicaltrials: gov; Unique identifier: MAGELLAN, NCT00571649. URL: https://www.
Clinicaltrials: gov; Unique identifier: MARINER, NCT02111564.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057847 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rationale: Prior work has shown a preference among most people with dementia and their families for comfort-focused care near the end-of-life. Nonetheless, intubation and mechanical ventilation are increasing over time without concurrent trends in improved survival, including among those with advanced dementia. A better understanding of prehospital decision-making about intubation for people with dementia will guide efforts to increase goal-concordant care at onset of critical illness.
View Article and Find Full Text PDFBackground: A critical need to increase Alzheimer's disease (AD) screening exists given rising incidence, new disease-modifying treatments, and ill-equipped primary care settings. This study assessed the feasibility of a novel, community-based AD screening program to increase cognitive and retinal-based assessments.
Methods: An observational study, supported by the Davos Alzheimer's Collaborative, assessed the utility of leveraging community-based settings to increase rates of cognitive assessment (conducted by Alzheimer Society (AS) social workers [SWs]) and RetiSpec's AI-based eye test in optometry settings to detect biologic signatures of AD (plus participant survey).
Dementia Care Practice.
Alzheimers Dement
December 2024
Global Brain Health Institute, University of California, San Francisco, CA, USA.
Background: The COVID-19 pandemic in Ethiopia posed additional challenges to an already strained mental health service. Eka Kotebe Hospital, the second-largest mental health facility with a capacity of 175 beds, was transformed into a dedicated COVID-19 treatment center, leaving mental health service users, especially vulnerable elderly patients with cognitive impairments, without adequate support. I had the challenge to implement alternatives to provide mental health services coverage to underserved elderly population.
View Article and Find Full Text PDFOlanzapine versus quetiapine in critically ill patients with hyperactive delirium: Protocol for a multicentre, cluster-randomised, double-crossover, pragmatic clinical trial (CALM-ICU).
Crit Care Resusc
December 2024
Department of Intensive Care, The Royal Melbourne Hospital, Melbourne, Australia.
Background: Patients in the intensive care unit (ICU) frequently develop hyperactive delirium, which may be accompanied by behaviour that increases clinical risks to themselves as well as other patients and staff. There is a paucity of evidence to inform the urgent enteral administration of antipsychotic drugs to treat such hyperactive delirium and behavioural disturbances.
Objective: The aim of this study is to test the efficacy and safety of administering enteral olanzapine when compared to quetiapine in critically ill patients with hyperactive delirium.
Objective: There is uncertainty about whether early infusion of intravenous amino acids confers clinical benefits in critically ill patients. In this study, we aimed to test the hypothesis that intravenous amino acids could improve 90-day mortality in critically ill patients with normal kidney function.
Design: This is a multicentre, open-label, randomised, parallel-controlled trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!